fluarix suspenzija za injiciranje v napolnjeni injekcijski brizgi
gsk d.o.o., ljubljana - ha seva nib-74xp (iz seva a/christchurch/16/2010, podoben sevu a/california/7/20; ha seva b/phuket/3073/2013; ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/9 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - ha seva nib-74xp (iz seva a/christchurch/16/2010, podoben sevu a/california/7/20 15 µg / 0,5 ml ha seva b/phuket/3073/201315 µg / 0,5 ml ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/915 µg / 0,5 ml; ha seva b/phuket/3073/2013 15 µg / 0,5 ml ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/915 µg / 0,5 ml; ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/9 15 µg / 0,5 ml - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano
vaxigrip suspenzija za injiciranje v napolnjeni injekcijski brizgi
sanofi pasteur - ha seva b/brisbane/60/2008, divji tip, podoben sevu b/brisbane/60/2008; ha seva nymc x-275 (iz seva a/michigan/45/2015, podoben sevu a/michigan/45/2015; ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/48 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - ha seva b/brisbane/60/2008, divji tip, podoben sevu b/brisbane/60/2008 15 µg / 0,5 ml ha seva nymc x-275 (iz seva a/michigan/45/2015, podoben sevu a/michigan/45/201515 µg / 0,5 ml ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/4815 µg / 0,5 ml; ha seva nymc x-275 (iz seva a/michigan/45/2015, podoben sevu a/michigan/45/2015 15 µg / 0,5 ml ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/4815 µg / 0,5 ml; ha seva nymc x-263b (iz seva a/hong kong/4801/2014), podoben sevu a/hong kong/48 15 µg / 0,5 ml - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano
fluarix suspenzija za injiciranje v napolnjeni injekcijski brizgi
gsk d.o.o., ljubljana - ha seva nib-74xp (iz seva a/christchurch/16/2010, podoben sevu a/california/7/20; ha seva b/phuket/3073/2013; ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/9 - suspenzija za injiciranje v napolnjeni injekcijski brizgi - ha seva nib-74xp (iz seva a/christchurch/16/2010, podoben sevu a/california/7/20 15 µg / 0,5 ml ha seva b/phuket/3073/201315 µg / 0,5 ml ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/915 µg / 0,5 ml; ha seva b/phuket/3073/2013 15 µg / 0,5 ml ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/915 µg / 0,5 ml; ha seva nib-88 (iz seva a/switzerland/9715293/2013, podoben sevu a/switzerland/9 15 µg / 0,5 ml - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano
verorab ne manj kot 2,5 i.u. inaktiviranega virusa stekline/1 odmerek (0,5 ml suspenzije) prašek in vehikel za suspenzijo za inj
nijz - prašek in vehikel za suspenzijo za injiciranje - cepivo proti steklini z inaktiviranimi virusi
twinrix paediatric
glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - cepiva - twinrix pediatric je indiciran za uporabo pri neimunskih dojenčkih, otrocih in mladostnikih od enega leta do vključno 15 let, pri katerih obstaja tveganje za okužbo s hepatitisom a in hepatitisom b.
ingelvac mycoflex
boehringer ingelheim vetmedica gmbh 55216 ingelheim/rhein nemČija 2 -
duramune pi + lc
ena viala liofilizirano komponento ki vsebuje živ -
gallimune se+st
boehringer ingelheim animal health france scs 29 -
fluad tetra
seqirus netherlands b.v. - a/darwin/9/2021 (h3n2) - like strain (a/darwin/6/2021, ivr-227) / a/victoria/4897/2022 (h1n1) pdm09-like strain (a/victoria/4897/2022, ivr-238) / b/phuket/3073/2013-like strain (b/phuket/3073/2013, bvr-1b) / influenza virus b/austria/1359417/2021-like strain (b/austria/1359417/2021, bvr-26) - gripa, človek - cepiva - profilaksa gripe pri starejših (65 let in starejši). fluad tetra je treba uporabljati v skladu z uradnimi priporočili.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.